Genetic variants linked to GLP-1 drug resistance identified in roughly 10% of population
A study has identified heritable variants that appear to reduce responsiveness to GLP-1 receptor agonists in clinical trials, potentially explaining why a subset of patients fail to reach glycaemic targets.
Researchers have identified a set of genetic variants associated with reduced responsiveness to GLP-1 receptor agonists — a class of drugs widely used to treat type 2 diabetes and, increasingly, obesity. According to reporting by ScienceDaily, the variants appear to affect approximately 10% of the population and were found to correlate with significantly lower rates of reaching healthy blood glucose targets in several clinical trials. The phenomenon has been described by the researchers as a form of "GLP-1 resistance," analogous in concept to insulin resistance.
The source lede does not identify the specific institution, research team, or journal involved in the primary publication; a full assessment of the finding awaits the peer-reviewed paper. The study appears to have been published or presented in proximity to the American Diabetes Association annual meeting in New Orleans, where GLP-1 research featured prominently.
If confirmed in peer review, the finding would have implications for pharmacogenomics research: understanding why a genetically defined subgroup responds poorly to a dominant class of metabolic drugs is a substantive question for translational genetics. It may also be relevant to the design of future clinical trials, which would need to account for variant carrier status in stratified analyses. Educators and students may note this as an emerging example of pharmacogenetic heterogeneity affecting a high-profile drug class. No clinical recommendations follow from a single unreplicated finding of this kind.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Scientists have found that certain inherited differences in DNA — carried by roughly one in ten people — may make GLP-1 drugs (sometimes called drugs like Ozempic or Wegovy) work less well for controlling blood sugar in type 2 diabetes. In clinical trials, people who carried these variants were less likely to reach their blood sugar targets while taking these medicines. Researchers are describing this as a kind of "GLP-1 resistance." The study has not yet been fully assessed by independent scientists, so it is too early to draw firm conclusions. This kind of research — looking at how our genes affect how we respond to medicines — is called pharmacogenomics. It helps scientists understand why the same drug can work differently in different people. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-06-05Scientists discover why ozempic may not work for some people